Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
V A JenkinsL J Fallowfield

Abstract

Trials of novel drugs used in advanced disease often show only progression-free survival or modest overall survival benefits. Hypothetical studies suggest that stabilisation of metastatic disease and/or symptom burden are worth treatment-related side effects. We examined this premise contemporaneously using qualitative and quantitative methods. Patients with metastatic cancers expected to live > 6 months and prescribed drugs aimed at cancer control were interviewed: at baseline, at 6 weeks, at progression, and if treatment was stopped for toxicity. They also completed Functional Assessment of Cancer Therapy (FACT-G) plus Anti-Angiogenesis (AA) subscale questionnaires at baseline then monthly for 6 months. Ninety out of 120 (75%) eligible patients participated: 41 (45%) remained on study for 6 months, 36 progressed or died, 4 had treatment breaks, and 9 withdrew due to toxicity. By 6 weeks, 66/69 (96%) patients were experiencing side effects which impacted their activities. Low QoL scores at baseline did not predict a higher risk of death or dropout. At 6-week interviews, as the side effect severity increased, patients were significantly less inclined to view the benefit of cancer control as worthwhile (X2 = 50.7, P < 0.001). Em...Continue Reading

References

Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F CellaJ Brannon
Oct 18, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P C Stone, S Lund
Nov 19, 2009·Journal of the National Cancer Institute·Ethan BaschDeborah Schrag
Sep 8, 2010·The New England Journal of Medicine·Jennifer S TemelThomas J Lynch
Jan 26, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey M PeppercornUNKNOWN American Society of Clinical Oncology
Oct 20, 2011·Nature Reviews. Clinical Oncology·Lesley J Fallowfield, Anne Fleissig
Nov 26, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Eitan AmirAlberto Ocaña
Mar 1, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·John F P BridgesA Brett Hauber
Mar 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher M Booth, Elizabeth A Eisenhauer
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Saroj NiraulaEitan Amir
Jul 24, 2015·JAMA Oncology·Holly G PrigersonPaul K Maciejewski
Oct 7, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea C EnzingerHolly G Prigerson
Jun 13, 2017·The Cochrane Database of Systematic Reviews·Markus W HaunMechthild Hartmann

❮ Previous
Next ❯

Software Mentioned

AVALPROFS

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.